Literature DB >> 20619400

Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources.

Mehdi Najar1, Gordana Raicevic, Hicham Id Boufker, Hussein Fayyad Kazan, Cécile De Bruyn, Nathalie Meuleman, Dominique Bron, Michel Toungouz, Laurence Lagneaux.   

Abstract

Due to their immunomodulatory properties, adipose tissue (AT) and Wharton's Jelly (WJ) constitute valuable alternatives to BM as sources of MSCs for managing graft-versus-host disease. To ensure the efficiency of AT- and WJ-MSCs implies the characterization of their immunomodulatory functions in comparison to those of BM. In this study, we investigated the capacity of AT- and WJ-MSCs to modulate lymphocyte reactions in response to different stimuli as well as the specificity of this immunomodulation. AT- and WJ-MSC displayed potent immunosuppressive effects on lymphocyte responses in a dose-dependent manner. These effects included the prevention of lymphocyte activation as well as the suppression of T-cell proliferation regardless of the stimuli used to activate lymphocytes. These effects were mediated through the expression of COX1/COX2 enzymes and by the production of PGE2. CD4(+) and CD8(+) T-lymphocytes were equally targeted by MSCs demonstrating that the immunomodulation was not restricted to a specific T-cell subpopulation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619400     DOI: 10.1016/j.cellimm.2010.06.006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  102 in total

Review 1.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

2.  Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Authors:  Reine El Omar; Yu Xiong; Gabriel Dostert; Huguette Louis; Monique Gentils; Patrick Menu; Jean-François Stoltz; Émilie Velot; Véronique Decot
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

3.  Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Authors:  Jorge Paz Rodriguez; Michael P Murphy; Soonjun Hong; Marialaura Madrigal; Keith L March; Boris Minev; Robert J Harman; Chien-Shing Chen; Ruben Berrocal Timmons; Annette M Marleau; Neil H Riordan
Journal:  Int Arch Med       Date:  2012-02-08

4.  Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.

Authors:  Zyrafete Kuçi; Julia Seiberth; Hatixhe Latifi-Pupovci; Sibylle Wehner; Stefan Stein; Manuel Grez; Halvard Bönig; Ulrike Köhl; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

5.  Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts.

Authors:  Sara M Melief; Jaap Jan Zwaginga; Willem E Fibbe; Helene Roelofs
Journal:  Stem Cells Transl Med       Date:  2013-05-21       Impact factor: 6.940

6.  Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

Authors:  O Parolini; F Alviano; A G Betz; D W Bianchi; C Götherström; U Manuelpillai; A L Mellor; R Ofir; P Ponsaerts; S A Scherjon; M L Weiss; S Wolbank; K J Wood; C V Borlongan
Journal:  Placenta       Date:  2011-05-14       Impact factor: 3.481

7.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

8.  Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming.

Authors:  Mehdi Najar; Gordana Raicevic; Hussein Fayyad-Kazan; Hussein Fayyad Kazan; Cécile De Bruyn; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

Review 9.  Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants.

Authors:  Ching-Shwun Lin; Guiting Lin; Tom F Lue
Journal:  Stem Cells Dev       Date:  2012-07-03       Impact factor: 3.272

Review 10.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.